A5080337749- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- Allergic Rhinitis and Sensitization
- Immunotherapy and Immune Responses
- Hidradenitis Suppurativa and Treatments
- Autoimmune Bullous Skin Diseases
- Colorectal and Anal Carcinomas
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- IL-33, ST2, and ILC Pathways
- melanin and skin pigmentation
- Urticaria and Related Conditions
- Cutaneous Melanoma Detection and Management
- Hair Growth and Disorders
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Skin and Cellular Biology Research
- Skin Protection and Aging
- Mast cells and histamine
Rockefeller University
2016-2025
Rockefeller University Hospital
1991-2024
Einstein Medical Center Philadelphia
2023
Bristol-Myers Squibb (Germany)
2014-2022
Sanofi (France)
2014-2022
Janssen (Belgium)
2014-2022
Pfizer (United Kingdom)
2022
Sanofi (Mexico)
2022
Regeneron (United States)
2022
Estée Lauder (United States)
2022
In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for treatment moderate-to-severe plaque psoriasis.We randomly assigned patients with score 12 or higher on psoriasis area-and-severity index (PASI, which scores range from 0 to 72, indicating more severe disease) 10% their body-surface area affected by receive (70 mg, 140 210 mg at day 1 weeks...
Psoriasis is a type I–deviated disease characterized by the presence of interferon (IFN)-γ and multiple IFN-related inflammatory genes in lesions. Because interleukin (IL)-23 now recognized to play role recruitment cells T helper cell (Th)1-mediated disease, we examined psoriasis skin lesions for production this newly described cytokine. IL-23 composed two subunits: unique p19 subunit p40 shared with IL-12. We found reliable increase mRNA quantitative reverse transcription polymerase chain...
Psoriasis is a common papulosquamous skin disease. The histopathology characterized by epidermal hyperplasia and inflammation. Recent studies suggest that keratinocyte proliferation inflammation in psoriasis are manifestations of the same underlying pathological process. Interleukin 6 (IL-6), cytokine major mediator host response to tissue injury infection, produced both keratinocytes leukocytes culture. IL-6 expression was studied psoriatic plaques immunoperoxidase staining with two...
Background Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines, yet the relative contribution of interferon (IFN)‐γ, interleukin (IL)‐17 IL‐22 on pathogenesis still unknown. Objectives In this study, we sought to identify cytokines produced skin‐resident T cells in normal skin, localize receptors for these examine how alter gene expression profiles bearing cognate receptors. Methods We used intracellular cytokine staining flow cytometry evaluate cell...
Biological agents have dramatically improved treatment options for patients with severe psoriasis. Etanercept (tumor necrosis factor [TNF] receptor-immunoglobulin fusion protein) is an effective many psoriasis patients, and blockade of TNF considered to be its primary action. However, in this clinical trial, we show that etanercept has early inhibitory effects on a newly appreciated type T cells: helper 17 (Th17) cells. reduced the inflammatory dendritic cell products drive Th17...
A genome-wide association study was performed to identify genetic factors involved in susceptibility psoriasis (PS) and psoriatic arthritis (PSA), inflammatory diseases of the skin joints humans. 223 PS cases (including 91 with PSA) were genotyped 311,398 single nucleotide polymorphisms (SNPs), results compared those from 519 Northern European controls. Replications an independent cohort 577 737 controls U.S., 576 PSA patients 480 U.K.. Strongest associations class I region major...
Engagement of the B7 family molecules on antigen-presenting cells with their T cell–associated ligands, CD28 and CD152 (cytotoxic lymphocyte–associated antigen-4 [CTLA-4]), provides a pivotal costimulatory signal in T-cell activation. We investigated role CD28/CD152 pathway psoriasis 26-week, phase I, open-label dose-escalation study. The importance this generation humoral immune responses to cell–dependent neoantigens, bacteriophage φX174 keyhole limpet hemocyanin, was also evaluated....
Dupilumab is an IL-4 receptor α mAb inhibiting signaling of and IL-13, key drivers type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, effects dupilumab on molecular/cellular lesional nonlesional skin phenotypes systemic 2 biomarkers moderate-to-severe atopic dermatitis (AD).Skin biopsy specimens blood were from 54 randomized 1:1 to weekly subcutaneous...